Literature DB >> 11754676

Persistent human papillomavirus infection as a predictor of cervical intraepithelial neoplasia.

N F Schlecht1, S Kulaga, J Robitaille, S Ferreira, M Santos, R A Miyamura, E Duarte-Franco, T E Rohan, A Ferenczy, L L Villa, E L Franco.   

Abstract

CONTEXT: Human papillomavirus (HPV) infection is believed to be the central cause of cervical cancer, although most of the epidemiological evidence has come from retrospective, case-control studies, which do not provide information on the dynamics of cumulative or persistent exposure to HPV infection.
OBJECTIVE: To assess the risks of cervical neoplasia related to prior persistent HPV infections. DESIGN AND
SETTING: Longitudinal study of the natural history of HPV infection and cervical neoplasia in women residing in the city of São Paulo, Brazil, which was conducted between November 1993 and March 1997 and involved repeated measurements of HPV and lesions with follow-up until June 2000. PARTICIPANTS: A total of 1611 women with no cytological lesions at enrollment and HPV test results available from the first 2 visits. MAIN OUTCOME MEASURE: Cervical specimens taken for Papanicolaou cytology and HPV testing every 4 months in the first year and twice yearly thereafter. Incident cervical cancer precursor lesions ascertained by expert review of all cytology smears.
RESULTS: The incidence rate of squamous intraepithelial lesions (SILs) was 0.73 per 1000 women-months (95% confidence interval [CI], 0.5-0.9) among women free of HPV at the 2 initial visits and 8.68 (95% CI, 2.3-15.1) among women with HPV type 16 or 18 infections persisting over both visits. Relative to those negative for HPV oncogenic types at both initial visits, the relative risk (RR) of incident SIL was 10.19 (95% CI, 5.9-17.6) for persistent infections with any known oncogenic HPV types. The equivalent RR of incident high-grade SIL was 11.67 (95% CI, 4.1-33.3). The RRs of lesions were considerably higher for persistent infections with HPV type 16 or 18.
CONCLUSION: A strong relationship exists between persistent HPV infections and SIL incidence, particularly for HPV types 16 and 18.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11754676     DOI: 10.1001/jama.286.24.3106

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  133 in total

1.  Prevalence of infection with carcinogenic human papillomavirus among older women.

Authors:  John W Sellors; Tina L Karwalajtys; Janusz A Kaczorowski; James B Mahony; Alice Lytwyn; Sylvia Chong; Joanna Sparrow; Attila Lorincz
Journal:  CMAJ       Date:  2002-10-15       Impact factor: 8.262

2.  Evaluation of any or type-specific persistence of high-risk human papillomavirus for detecting cervical precancer.

Authors:  Morgan A Marks; Philip E Castle; Mark Schiffman; Patti E Gravitt
Journal:  J Clin Microbiol       Date:  2011-12-07       Impact factor: 5.948

3.  HPV typing and its relation with apoptosis in cervical carcinoma from Indian population.

Authors:  M Shabbir Alam; Asgar Ali; Syed Jafar Mehdi; Nisreen Sherif Alyasiri; Zakia Kazim; Swaraj Batra; A K Mandal; M Moshahid Alam Rizvi
Journal:  Tumour Biol       Date:  2011-09-20

4.  Persistence of newly detected human papillomavirus type 31 infection, stratified by variant lineage.

Authors:  Long Fu Xi; Mark Schiffman; Laura A Koutsky; Zhonghu He; Rachel L Winer; Ayaka Hulbert; Shu-Kuang Lee; Yang Ke; Nancy B Kiviat
Journal:  Int J Cancer       Date:  2012-07-11       Impact factor: 7.396

5.  The females against cancer educational series: a qualitative evaluation of mother/daughter knowledge and perceptions of human papillomavirus and its related cancers.

Authors:  Tasha R Louis-Nance; Minnjuan W Flournoy; Karen S Clinton; Krystle Hightower; Neethu Sebastian; Larrell L Wilkinson; Saundra H Glover
Journal:  J Natl Med Assoc       Date:  2012 Mar-Apr       Impact factor: 1.798

6.  Reversal of human papillomavirus-specific T cell immune suppression through TLR agonist treatment of Langerhans cells exposed to human papillomavirus type 16.

Authors:  Laura M Fahey; Adam B Raff; Diane M Da Silva; W Martin Kast
Journal:  J Immunol       Date:  2009-03-01       Impact factor: 5.422

Review 7.  Regulation of apoptosis by the papillomavirus E6 oncogene.

Authors:  Ting-Ting Li; Li-Na Zhao; Zhi-Guo Liu; Ying Han; Dai-Ming Fan
Journal:  World J Gastroenterol       Date:  2005-02-21       Impact factor: 5.742

Review 8.  Screening for cancer: valuable or not?

Authors:  Frank L Meyskens
Journal:  Curr Oncol Rep       Date:  2004-11       Impact factor: 5.075

9.  Invited commentary: Human papillomavirus infection and risk of cervical precancer--using the right methods to answer the right questions.

Authors:  Eduardo L Franco; Joseph Tota
Journal:  Am J Epidemiol       Date:  2009-12-10       Impact factor: 4.897

10.  Comparison of linear array and line blot assay for detection of human papillomavirus and diagnosis of cervical precancer and cancer in the atypical squamous cell of undetermined significance and low-grade squamous intraepithelial lesion triage study.

Authors:  Philip E Castle; Patti E Gravitt; Diane Solomon; Cosette M Wheeler; Mark Schiffman
Journal:  J Clin Microbiol       Date:  2007-11-07       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.